Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q4 2025 Earnings Call Transcript March 5, 2026 Atea Pharmaceuticals, Inc. misses on ...

Although major pharmaceutical companies have fallen in line with President Donald Trump’s “most favored nation” (MFN) drug pricing agenda, the specifics of their negotiated concessions and the actu | ...

Taiwan is mapping out a four-year national pharmaceutical resilience preparedness program that aims to bolster the country’s domestic drug supply with a 24 billion new Taiwan dollar ($755 million) | ...

Cash and Investments -- $301.8 million as of December 31, 2025, sufficient to fully fund current Phase III HCV and new HEV programs through 2027. Phase III HCV Trials -- C BEYOND enrollment completed ...

The End the Vaccine Carveout Act would expose vaccine makers to lawsuits that once drove companies out of the industry.

The legislation pending in the General Assembly is a Senate amendment to House Bill 2371. Sponsored by Sen. Dave Koehler, ...

Statistically significant (p<0.0001) and clinically meaningful improvement in Hamilton Anxiety Rating Scale (“HAM-A”) of ~10 ...

Advocates for health care providers that treat low-income and uninsured patients are pressuring state lawmakers to pass ...

A health assurance veterinarian for PIC, Rebecca Robbins was installed as president, succeeding Locke Karriker.

A new Ohio bill won't expand the 340B program, but it will protect patients' ability to fill prescriptions at their pharmacy of choice.

The VDH has not answered questions about how much money it erroneously overbilled a pharmaceutical manufacturer and may have to pay back, despite the issue triggering significant cuts to HIV services.

The bill passed the Senate on a largely party line vote of 17 to 10 late last month. But according to Sen. Deb Patterson, a Salem Democrat who chairs the Senate Health Care Committee, she was told ...